Meliodays and Celanese Collaborate on Hormone-Free IUD for Menstrual Pain

Meliodays Medical GmbH and Celanese Corporation have teamed up to advance the development of MelioOne®, a groundbreaking hormone-free, non-contraceptive intrauterine device (IUD) aimed at relieving menstrual pain. This collaboration leverages Celanese's VitalDose® Drug Delivery Platform, renowned for its reliable, controlled-release capabilities, to enhance Meliodays' innovative IUD design paired with a non-hormonal active pharmaceutical ingredient.

Simone Sabbione, CEO of Meliodays, highlighted that over 80% of menstruating individuals experience debilitating period pain. The MelioOne® IUD targets this pain at its source, potentially replacing oral medications that come with systemic side effects. Celanese's Brian Duke expressed optimism that this collaboration could lead to widespread adoption of this innovative solution in medical treatment plans.

The alliance marks a significant step forward in providing a more natural and pain-free menstrual experience for women, addressing a pressing unmet medical need with a localized therapy.